Conflict of Interest Waiver Details For Cmte. Members Should Be Public – BMS
This article was originally published in The Tan Sheet
Executive Summary
FDA advisory committee members granted conflict of interest waivers should be required to disclose the companies to which they have financial ties, Bristol-Myers Squibb maintains in comments to FDA
You may also be interested in...
‘High Dollar’ Conflicts Should Nullify FDA Advisory Panelists – Public Citizen
FDA advisory committee members with large financial conflicts of interest should be recused from meetings in which these conflicts may come into play, Public Citizen recommends after conducting a study on voting patterns
‘High Dollar’ Conflicts Should Nullify FDA Advisory Panelists – Public Citizen
FDA advisory committee members with large financial conflicts of interest should be recused from meetings in which these conflicts may come into play, Public Citizen recommends after conducting a study on voting patterns
‘High Dollar’ Conflicts Should Nullify FDA Advisory Panelists – Public Citizen
FDA advisory committee members with large financial conflicts of interest should be recused from meetings in which these conflicts may come into play, Public Citizen recommends after conducting a study on voting patterns